Evidence map›Paper›PMID 40659933›Full record

ArticleEuropean biophysics journal : EBJ2025

Specific TP53 mutations impair the recruitment of 53BP1 to DNA double-strand breaks underlying the mechanism of radioresistance.

Paolo Fagherazzi, Lenka Stixová, Eva Bartova

Abstract read
In one paragraph

Article in European biophysics journal : EBJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paolo FagherazziDepartment of Cell Biology & Epigenetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. fagher@ibp.cz.
Lenka StixováDepartment of Cell Biology & Epigenetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
Eva BartovaDepartment of Cell Biology & Epigenetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. bartova@ibp.cz.ORCID http://orcid.org/0000-0003-1299-0470

Funding

Biofyzikální Ústav, Akademie Věd České Republiky 68081707Grantová Agentura České Republiky 22-20303M
6 · The paper itself

Abstract

The tumor suppressor p53, extensively studied for over 40 years, is a key regulator of various cellular pathways, often functioning independently of its transcriptional activity. Notably, p53 has been shown to play a crucial role in DNA repair, not only in sensing DNA damage but also in influencing repair pathway choice. This work assesses the influence of p53 on the recruitment and activity of the NHEJ mediator 53BP1, focusing specifically on common p53 hotspot mutations found in human cancers. The aim is to understand how these mutations impair DNA damage response mechanisms and contribute to genetic instability, which enhances tumor survival. Analysis of p53 missense mutations (R248W, R273C, G245S) revealed mutation-specific effects on 53BP1 and RIF1 recruitment, with G245S retaining wild-type-like 53BP1 recruitment but still exhibiting enhanced BRCA1 foci formation. Given the widespread activation of NHEJ throughout the cell cycle, especially in response to radiotherapy and chemotherapy, gaining insight into how p53 mutations affect this response is vital for developing future therapeutic strategies.

Indexed as

DNA Breaks, Double-StrandedMutationRadiation ToleranceTumor Suppressor p53-Binding Protein 1Tumor Suppressor Protein p53Cell Line, TumorHumansTelomere-Binding ProteinsRif1 protein, humanTelomere-Binding ProteinsTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1Tumor Suppressor Protein p5353BP1ChromatinDNA repairEpigeneticsTP53

Identifiers

PMID40659933
PMCPMC12678470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.